

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT4915381

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
HOWARD HUGHES MEDICAL INSTITUTE	11/18/2016
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	Salk Institute for Biological Studies
<b>Street Address:</b>	10010 N. Torrey Pines Road
<b>City:</b>	La Jolla
<b>State/Country:</b>	CALIFORNIA
<b>Postal Code:</b>	92037-1002
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	15952516
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(503)595-5301
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	503-595-5300
<b>Email:</b>	deborah.martin@klarquist.com
<b>Correspondent Name:</b>	S.L. RYBAK PH.D, KLARQUIST SPARKMAN, LLP
<b>Address Line 1:</b>	121 SW SALMON STREET
<b>Address Line 2:</b>	ONE WORLD TRADE CENTER, SUITE 1600
<b>Address Line 4:</b>	PORTLAND, OREGON 97204-2988
<b>ATTORNEY DOCKET NUMBER:</b>	7158-95852-07
<b>NAME OF SUBMITTER:</b>	SHEREE LYNN RYBAK, PH.D.
<b>SIGNATURE:</b>	/Sheree Lynn Rybak/
<b>DATE SIGNED:</b>	04/13/2018
<b>Total Attachments: 3</b>	
source=Assignment (HHMI to Salk)#page1.tif	
source=Assignment (HHMI to Salk)#page2.tif	
source=Assignment (HHMI to Salk)#page3.tif	

## ASSIGNMENT

This Assignment is made from the **HOWARD HUGHES MEDICAL INSTITUTE** (Assignor), having a place of business at 4000 Jones Bridge Road, Chevy Chase, MD 20815-6789 to the **SALK INSTITUTE FOR BIOLOGICAL STUDIES** (Assignee), having a place of business at 10010 N. Torrey Pines Road, La Jolla, California 92037.

WHEREAS, Assignor is an owner of the invention entitled "TREATMENT OF STEROID-INDUCED HYPERGLYCEMIA WITH FIBROBLAST GROWTH FACTOR (FGF) 1 ANALOGS", set forth in:

U.S. Provisional Patent Application No. 62/248,935, filed on October 30, 2015, entitled "TREATMENT OF STEROID-INDUCED HYPERGLYCEMIA WITH FIBROBLAST GROWTH FACTOR (FGF) 1 ANALOGS";

PCT Patent Application No. PCT/US2016/059190, filed on October 27, 2016, entitled "TREATMENT OF STEROID-INDUCED HYPERGLYCEMIA WITH FIBROBLAST GROWTH FACTOR (FGF) 1 ANALOGS";

WHEREAS, Assignor desires to have a recordable instrument assigning its entire right, title and interest in and to said invention, said application and any Letters Patent that may be granted for said invention in the United States and throughout the world to Assignee;

NOW THEREFORE, in accordance with the obligations to assign the invention and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignor sells, assigns, and transfers to Assignee, its entire right, title, and interest in and to said invention, said application and any Letters Patent that may be granted for said invention in the United states and throughout the world, including the right to file foreign applications directly in the name of Assignee and to claim for any such foreign applications any priority rights to which such applications are entitled under international conventions, treaties, or otherwise.

Assignor agrees that, upon request and without further compensation, but at no expense to Assignor, its legal representatives and assigns will do all lawful acts, including the execution of papers and the giving of testimony, that may be necessary or

desirable for obtaining, sustaining, reissuing, or enforcing Letters Patent in the United States and throughout the world for said invention, and for perfecting, recording, or maintaining the title of Assignee, its successors and assigns, to said invention, said application, and any Letters Patent granted for said invention in the United States and throughout the world.

Assignor represents and warrants that it has not granted and will not grant to others any rights inconsistent with the rights granted herein.

Assignor authorizes and requests the Commissioner of Patents and Trademarks of the United States and of all foreign countries to issue any Letters Patent granted for said invention, whether on said application or on any subsequently filed division, continuation, continuation-in-part or reissue application, to Assignee, its successors and assigns, as the assignee of its entire interest in said invention.

IN WITNESS WHEREOF, Assignor has executed this Assignment on the date(s) provided below.


HOWARD HUGHES MEDICAL INSTITUTE

Date: 11/18/16



Ronald M. Evans  
For himself and as Agent for the  
Howard Hughes Medical Institute


Witnessed by: Name MURIEL A. BOOGS  
Please Print or Type Name

Signature: 

The undersigned is authorized to sign this document on behalf of **Salk Institute for Biological Studies**.

Executed at La Jolla, CA on the 16 day of November, 2016.

**SALK INSTITUTE FOR BIOLOGICAL STUDIES**

By 

Name (typed or printed) Michelle Booden, Ph.D.

Title (typed or printed) Senior Director, Technology Development